2024 EMPO大会显示,T-DXd在先进的HER2-呈阳性的乳腺癌中表现出了显著的无进展生存和脑肿瘤减少。 2024 ESMO Congress reveals T-DXd demonstrated significant progression-free survival and brain tumor reduction in advanced HER2-positive breast cancer.
达纳- 法伯癌症研究所领导的临床试验显示,特拉斯图祖马布德鲁克斯泰坎 (T- DXd) 有效地对抗晚期HER2阳性乳腺癌中大脑转移. A clinical trial led by Dana-Farber Cancer Institute revealed trastuzumab deruxtecan (T-DXd) is effective against brain metastases in advanced HER2-positive breast cancer. DESTINY-Breast12号试验显示,中位无进展的存活率为17.3个月,71%的病人脑部肿瘤减少,90%的病人在治疗一年后存活。 The DESTINY-Breast12 trial showed a median progression-free survival of 17.3 months, with 71% of patients experiencing tumor reduction in the brain and 90% surviving one year after treatment. 这些在2024年ESMO大会上提出的研究结果表明T-DXd可能是关键的治疗选择. The findings, presented at the ESMO Congress 2024, suggest T-DXd could be a key treatment option.